Nebula Research & Development LLC Biomarin Pharmaceutical Inc Transaction History

Nebula Research & Development LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	$54.08 - $68.32 $982,687 - $1.24 Million	18,171 Added 101.51%	36,071 $1.98 Billion
Q1 2025 May 15, 2025	SELL	$61.25 - $72.83 $1.55 Million - $1.84 Million	-25,285 Reduced 58.55%	17,900 $1.27 Billion
Q4 2024 Feb 14, 2025	SELL	$61.93 - $70.49 $589,202 - $670,641	-9,514 Reduced 18.05%	43,185 $2.84 Billion
Q3 2024 Nov 14, 2024	BUY	$69.02 - $93.84 $3.64 Million - $4.95 Million	52,699 New	52,699 $3.7 Billion
Q1 2024 May 15, 2024	BUY	$83.81 - $99.0 $428,604 - $506,286	5,114 New	5,114 $447 Million

667

182M

1.48M

957K

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $10.2B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Nebula Research & Development LLC, based on Form 13F filings with the SEC.

Stay updated on Nebula Research & Development LLC with notifications on news.